Effect of ATRA and Selective RAR Agonists on NB4 Cell Differentiation
| Cell Line . | Treatment . | NBT Reduction (ΔOD/h) . | CD11b (% positive cells) . | CD33 (% positive cells) . |
|---|---|---|---|---|
| S-NB4 | Control | 32 ± 4 | 5.8 ± 3.0 | 96.8 ± 4.8 |
| ATRA | 110 ± 10-150 | 31.6 ± 5.0-150 | 83.0 ± 8.8-150 | |
| R-NB4.306 | Control | 34 ± 6 | 4.9 ± 1.4 | 98.6 ± 1.2 |
| ATRA | 35 ± 3 | 5.6 ± 0.2 | 98.2 ± 1.1 | |
| R-NB4.007/6 | Control | 31 ± 4 | 4.7 ± 2.8 | 94.0 ± 7.2 |
| ATRA | 34 ± 8 | 5.9 ± 4.9 | 94.3 ± 4.4 | |
| S-NB4 | Control | 29 ± 6 | 5.8 ± 3.0 | 96.8 ± 4.8 |
| AM580 | 190 ± 12-150 | 56.21 ± 5-150 | 73.2 ± 7.6-150 | |
| CD2019 | 30 ± 7 | 6.1 ± 4.3 | 91.8 ± 4.9 | |
| CD437 | 27 ± 5 | 5.3 ± 4.1 | 91.9 ± 6.2 |
| Cell Line . | Treatment . | NBT Reduction (ΔOD/h) . | CD11b (% positive cells) . | CD33 (% positive cells) . |
|---|---|---|---|---|
| S-NB4 | Control | 32 ± 4 | 5.8 ± 3.0 | 96.8 ± 4.8 |
| ATRA | 110 ± 10-150 | 31.6 ± 5.0-150 | 83.0 ± 8.8-150 | |
| R-NB4.306 | Control | 34 ± 6 | 4.9 ± 1.4 | 98.6 ± 1.2 |
| ATRA | 35 ± 3 | 5.6 ± 0.2 | 98.2 ± 1.1 | |
| R-NB4.007/6 | Control | 31 ± 4 | 4.7 ± 2.8 | 94.0 ± 7.2 |
| ATRA | 34 ± 8 | 5.9 ± 4.9 | 94.3 ± 4.4 | |
| S-NB4 | Control | 29 ± 6 | 5.8 ± 3.0 | 96.8 ± 4.8 |
| AM580 | 190 ± 12-150 | 56.21 ± 5-150 | 73.2 ± 7.6-150 | |
| CD2019 | 30 ± 7 | 6.1 ± 4.3 | 91.8 ± 4.9 | |
| CD437 | 27 ± 5 | 5.3 ± 4.1 | 91.9 ± 6.2 |
Cells were grown in the presence of 10−6 mol/L ATRA or 10−8 mol/L RAR agonists (AM580 = RARα agonist; CD2019 = RARβ agonist; CD437 = RARγ agonist) or the vehicle (control) for 96 hours. Washed cells were analyzed for NBT reduction activity and surface-marker CD11b and CD33 expression. Results are mean ± SD of five experiments (determinations in duplicate).
P < .01 compared with controls. Statistics for S-NB4 adjusted for multiple comparisons.